Alaunos Therapeutics (TCRT)
(Delayed Data from NSDQ)
$3.76 USD
-0.01 (-0.27%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $3.77 +0.01 (0.27%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TCRT 3.76 -0.01(-0.27%)
Will TCRT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TCRT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TCRT
J&J (JNJ) Updates 2023 Guidance After Final Kenvue Separation
Merck (MRK), Eisai to End Keytruda-Lenvima Combo Cancer Study
TCRT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%
Here's Why You Should Add Pacira (PCRX) Stock to Your Portfolio
Alaunos (TCRT) Stock Sinks As Market Gains: What You Should Know
Other News for TCRT
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
ZIOPHARM Oncology trading halted, news pending
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Intraday Session
TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024